To evaluate the potential for ctDNA to identify melanoma patients at high risk of relapse following surgery with curative intent, we analyzed ctDNA in the plasma from 161 patients carrying either a BRAF or NRAS mutation in their baseline resected tumor (Table 1 and supplementary Tables S1 and S2, available at Annals of Oncology online). This evidence concerns the gene BRAF and neoplasm.